Arimidex vs Aromasin: Steroidal vs Non-Steroidal Aromatase Inhibitors and When to Use Each
Every forum thread about Arimidex vs Aromasin on cycle eventually devolves into the same claim: “Aromasin is better because it does not cause oestrogen rebound and is easier on lipids.” The first half of that sentence is pharmacologically accurate. The second half is repeated so confidently that most users assume it is settled science, when in reality it is based on breast cancer data in postmenopausal women and has never been validated in a single randomised trial in men. The actual picture is more nuanced, and the choice between Anastrozole (Arimidex) and Exemestane (Aromasin) depends on your specific cycle, your health markers, and how aggressively you need to control oestrogen. Hemi Pharma UK stocks Anastrozole 1mg with full Janoshik verification, and this article explains exactly when each AI is the right tool and when neither should be used at all.
What is the fundamental difference between Arimidex and Aromasin?
Both drugs lower oestrogen by inhibiting aromatase, the enzyme (CYP19A1) that converts androgens to oestrogens. But they do it through completely different chemical mechanisms, and this mechanistic difference has practical consequences for how quickly oestrogen returns when you stop taking the drug, how your body replaces the inhibited enzyme, and what happens if you accidentally take too much.
Anastrozole (Arimidex) is a non-steroidal, reversible competitive inhibitor. It binds to the active site of the aromatase enzyme and blocks oestrogen production, but it does not destroy the enzyme. The aromatase molecule remains intact and functional; Anastrozole simply sits in the active site and prevents the androgen substrate from entering. When Anastrozole is cleared from the body (half-life approximately 46 hours), the enzyme is immediately available to resume aromatisation. This is the basis of the “oestrogen rebound” concern: if you stop Anastrozole abruptly after prolonged use, all the intact aromatase enzymes resume full activity simultaneously, potentially causing a transient spike in oestrogen above pre-treatment levels.
Exemestane (Aromasin) is a steroidal, irreversible inhibitor, often called a “suicide inhibitor.” Its chemical structure is based on androstenedione, the natural aromatase substrate. Exemestane binds to the aromatase active site and is processed as though it were a normal substrate, but during processing it forms a covalent bond that permanently deactivates the enzyme. The aromatase molecule is destroyed and can never function again. The body must synthesise entirely new aromatase protein to replace it, which takes approximately 2 to 3 days. This means there is no immediate rebound when Exemestane is discontinued: oestrogen levels rise gradually as new enzyme is produced, not abruptly as with Anastrozole.
Is the oestrogen rebound from Arimidex a real clinical problem?
The oestrogen rebound is real in pharmacokinetic terms: when a reversible inhibitor is cleared, the previously occupied enzymes resume activity, and if enzyme levels have been upregulated during treatment (the body’s compensatory response to low oestrogen), the total aromatase capacity may temporarily exceed pre-treatment levels. In practice, however, the clinical significance of this rebound in male steroid users is debated.
For users who taper their AI dose towards the end of a cycle (rather than stopping abruptly), the rebound effect is minimised because aromatase capacity ramps up gradually. For users who stop Anastrozole at the same time as their last steroid injection, the practical impact is limited because androgen levels (the substrate for aromatisation) are also falling simultaneously, meaning there is less to aromatise even if enzyme capacity spikes.
The scenario where rebound matters most is if a user stops Anastrozole abruptly while still running high-dose aromatisable compounds. In this specific situation, the combination of abundant substrate and fully restored (or upregulated) enzyme capacity can produce a rapid oestrogen spike that triggers gynaecomastia symptoms. This is avoidable with either a taper or by switching to Exemestane for the final weeks of the cycle. It is not a reason to categorically prefer one AI over the other for the entire duration of use.
Is Aromasin actually better for lipids than Arimidex?
This is where the popular claim falls apart under scrutiny. The idea that Exemestane is “lipid-friendly” comes from two sources, both of which have significant limitations when applied to male steroid users.
The first source is the MA.27 trial, the largest head-to-head comparison of Exemestane and Anastrozole, conducted in over 7,500 postmenopausal women with breast cancer. The MA.27 data showed that hypertriglyceridaemia and hypercholesterolaemia were less frequent in the Exemestane group than the Anastrozole group. This is the finding that gets quoted. What does not get quoted is that the trial was conducted in postmenopausal women (a fundamentally different hormonal context from a man on 500mg of testosterone per week), and that the differences, while statistically significant in a 7,500-patient trial, were clinically modest.
The second source is a 2020 prospective cohort study by Wang and colleagues comparing steroidal and non-steroidal AIs in postmenopausal breast cancer patients. This study actually found that HDL-cholesterol was significantly lower in the steroidal (Exemestane) group at most time points, though the overall incidence of cumulative lipid events was lower with steroidal AIs. The picture is mixed, not cleanly in Exemestane’s favour.
In men, there is exactly one relevant study. Leder and colleagues (2004) examined Anastrozole 1mg daily in elderly hypogonadal men and found neutral-to-mildly-negative effects on HDL. No equivalent male study exists for Exemestane. The claim that Exemestane is “better for lipids in men” is therefore an extrapolation from female breast cancer data, not a conclusion from male-specific evidence. It may well be true, but it has not been demonstrated.
What is unambiguously true for steroid users is that the biggest determinant of lipid disruption on cycle is the steroid itself (particularly 17-alpha-alkylated oral steroids), not which AI you use. The HDL suppression from 50mg of Winstrol daily dwarfs any differential lipid effect between Anastrozole and Exemestane. Optimising lipid health on cycle means minimising oral steroid duration, maintaining cardiovascular exercise, and monitoring bloodwork, not switching AI brands.
Does Exemestane’s androgenic metabolite provide a real-world benefit?
Exemestane is structurally derived from androstenedione, and its primary metabolite, 17-hydroxy-exemestane, has mild androgenic activity. This is frequently cited as an advantage: “Aromasin has a mild anabolic/androgenic effect that Arimidex does not.” In breast cancer patients, this androgenic metabolite may contribute to Exemestane’s slightly more favourable bone density profile (androgens promote osteoblast activity). In male steroid users who are already running supraphysiological doses of androgens, the incremental androgenic contribution of 17-hydroxy-exemestane is pharmacologically trivial. It is not going to meaningfully affect your muscle mass, strength, or libido on top of 500mg of testosterone per week.
When should you use Arimidex on a steroid cycle?
Anastrozole is the more commonly used AI among UK steroid users, primarily because of availability, familiarity, and the extensive clinical data supporting its use in men (it is prescribed off-label for male oestrogen management in TRT clinics across the UK). Practical considerations for Anastrozole on cycle:
Starting dose: 0.25mg to 0.5mg every other day with aromatisable compounds at moderate doses (300mg to 500mg testosterone weekly). This is a starting point, not a fixed protocol. The correct dose is determined by mid-cycle bloodwork showing oestradiol within the male reference range (typically 80 to 160 pmol/L or 20 to 40 pg/mL, though optimal ranges vary by individual).
Timing: take Anastrozole on injection days for consistency. Its 46-hour half-life means every-other-day dosing maintains reasonably stable aromatase inhibition.
Adjustment: if mid-cycle bloods show oestradiol above range with symptoms (water retention, nipple sensitivity, mood changes), increase frequency to daily dosing at 0.25mg to 0.5mg. If oestradiol is below range or you have symptoms of low oestrogen (dry joints, flat mood, low libido, cognitive fog), reduce or discontinue the AI entirely. Crashing oestrogen is worse than running it slightly high, a point covered extensively in our steroid side effects guide and Proviron vs Anastrozole comparison.
When should you use Aromasin instead?
Exemestane is the better choice in three specific scenarios. First, if you have experienced oestrogen rebound symptoms after discontinuing Anastrozole on a previous cycle, Exemestane’s irreversible mechanism eliminates this risk. Second, if you are running a cycle that transitions directly into PCT without a clearance window (short-ester compounds where PCT starts within days of the last injection), the absence of rebound with Exemestane is advantageous during the sensitive early PCT period. Third, if bloodwork shows that your lipid profile responds particularly poorly to Anastrozole (HDL dropping disproportionately), switching to Exemestane for the next cycle and comparing bloods is a reasonable approach.
Exemestane dosing on cycle: 12.5mg every other day is the standard starting point with moderate-dose aromatisable compounds. Exemestane must be taken with a fat-containing meal for adequate absorption (its bioavailability increases approximately 40% with food). Its half-life is approximately 24 hours, but because it permanently inactivates aromatase and new enzyme synthesis takes 2 to 3 days, the effective duration of action is longer than the plasma half-life suggests. Dosing every other day is therefore sufficient for most users.
When should you use neither AI?
This is the question most users never ask, and it is the most important one. Many steroid cycles do not require an aromatase inhibitor at all. Cycles using only non-aromatising compounds (Anavar, Winstrol, Masteron, Trenbolone, Proviron) produce no oestrogen through aromatisation and do not require AI management. Testosterone at TRT doses (100mg to 200mg weekly) rarely produces clinically significant oestrogen elevation in men with normal body fat levels.
Even at moderate supraphysiological testosterone doses (300mg to 500mg weekly), many men do not aromatise sufficiently to need an AI. The decision to introduce an AI should be based on bloodwork showing elevated oestradiol combined with clinical symptoms, not on a prophylactic protocol started on day one. Running an AI “just in case” is one of the most common mistakes in steroid use because the consequences of unnecessarily low oestrogen (joint pain, cognitive impairment, lipid deterioration, sexual dysfunction, bone density loss) are clinically worse than the consequences of running oestrogen slightly above range.
Oestrogen is not the enemy. It is an essential hormone for bone health, cardiovascular function, cognitive performance, libido, and mood. The goal of AI use is to prevent symptomatic excess, not to eliminate oestrogen. Bloodwork-guided dosing, as detailed in our beginner guide and PCT guide, is the only responsible approach.
For independently tested Anastrozole with published Janoshik lab results, Hemi Pharma provides full product verification before sale.
Frequently Asked Questions
Is Arimidex or Aromasin stronger at lowering oestrogen?
Both are highly potent aromatase inhibitors that can suppress oestrogen by 80% to 95% at standard doses. Exemestane’s irreversible mechanism does not make it “stronger” per dose; it makes the inhibition more persistent per enzyme molecule. In practice, both are capable of crashing oestrogen if overdosed, which is the greater clinical risk. The correct dose of either drug is the minimum that keeps oestradiol within the male reference range on bloodwork.
Can you switch from Arimidex to Aromasin mid-cycle?
Yes. If you started with Anastrozole and want to switch to Exemestane (or vice versa), you can do so at any point. There is no pharmacological interaction between the two that prevents switching. Allow one to two days for Anastrozole to clear before starting Exemestane, or simply begin Exemestane on the next scheduled AI day. Adjust dosing based on follow-up bloodwork.
Does Aromasin cause less joint pain than Arimidex?
Joint pain from aromatase inhibitors is caused by low oestrogen, not by the specific AI used. If you crash your oestrogen with Exemestane, you will get the same joint pain as if you crashed it with Anastrozole. The perception that Aromasin causes less joint pain likely reflects two factors: Exemestane’s androgenic metabolite may provide mild joint-protective effects, and Exemestane’s irreversible mechanism may produce slightly more stable oestrogen levels with less risk of overshoot-and-crash dosing patterns.
Do you need an AI on a cutting cycle?
It depends on the compounds. If your cutting cycle uses only non-aromatising compounds (Anavar, Winstrol, Masteron, Trenbolone) with a testosterone base at TRT doses, an AI is unlikely to be necessary. If your testosterone dose is higher (300mg or above), mid-cycle bloodwork should guide the decision. Lower body fat percentages are associated with lower aromatisation rates, so cutting phases may naturally require less AI than bulking phases at the same testosterone dose.
Should you use an AI during PCT?
Generally no. During PCT, the goal is to restore endogenous testosterone production through SERM-mediated LH and FSH stimulation. Adding an AI during PCT further suppresses oestrogen at a time when your body needs adequate oestrogen for bone health, lipid metabolism, and sexual function. SERMs provide targeted oestrogen receptor blockade at the pituitary without crashing systemic oestrogen, which is why they are the standard PCT drugs rather than AIs.
References
Goss PE, Ingle JN, Chapman JA, et al. Final analysis of NCIC CTG MA.27: exemestane versus anastrozole as initial adjuvant therapy. Cancer Res. 2010;70(24 Suppl):S1-1. Presented at San Antonio Breast Cancer Symposium. OncLive Report
Wang X, Zhu A, Wang J, et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. Ther Adv Med Oncol. 2020;12:1758835920925991. doi:10.1177/1758835920925991
Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89(3):1174-1180.
Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22):5126-5137.